Equillium Results Presentation Deck

Approved Therapies: Need Remains for Rapid & Deep Responses Despite recent approvals, high unmet medical need remains for therapies that induce rapid and deep responses in more patients safely, without broad immuno-suppression ORR 50% Baseline UPCR Mean (SD) 20% 30% 50% 23% 29% 48% 6mo 12mo Placebo 3.9 (2.4) ORR 52% ORR 70% > Lupkynis (voclosporin) 1. Rovin et al., The Lancet, 2021; 2. Furie et al., NEJM, 2020 32% 38% 30% 6mo Drug capsules 41% 29% 30% 12mo 4.1 (2.7) ORR 70% Data from the Phase 3 AURORA-1¹ and BLISS-LN2 trials. Note FDA approved Benlysta on primary efficacy renal response (PERR) defined as UPCR <0.7 g/g.¹ equillium ORR 37% 20% 17% 63% 24mo Placebo 3.5 (3.6) Benlysta (belimumab) 30% 18% 52% 24mo Drug 3.2 (2.7) ORR 48% Complete Response: < 0.5 g/g Partial Response: > 50% reduction UPCR No Response: < 50% reduction or worsening UPCR a

View entire presentation